Evidence map›Paper›PMID 37525792›Full record

ReviewCureus2023

Exploring the Effectiveness and Safety of Azilsartan-Medoxomil/Chlorthalidone Versus Olmesartan-Medoxomil/Hydrochlorothiazide in Hypertensive Patients: A Meta-Analysis.

Lakshya Kumar, Sundal Khuwaja, Aanand Kumar, Unaib Ahmed Memon, Munesh Kumar, Arpana Ashok, Manisha Lohana, Ahmed Qudoos, Maham Kashif, Mahima Khatri and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lakshya KumarGeneral Medicine, Pandit Dindayal Upadhyay (PDU) Medical College, Rajkot, IND.
Sundal KhuwajaMedicine, Liaquat University of Medical and Health Sciences, Jamshoro, PAK.
Aanand KumarInternal Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, PAK.
Unaib Ahmed MemonInternal Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, PAK.
Munesh KumarMedicine, Liaquat University of Medical and Health Sciences, Jamshoro, PAK.
Arpana AshokDepartment of Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK.
Manisha LohanaMedicine, Liaquat University of Medical and Health Sciences, Jamshoro, PAK.
Ahmed QudoosMedicine, Liaquat University of Medical and Health Sciences, Jamshoro, PAK.
Maham KashifMedicine, Khawaja Muhammad Safdar Medical College, Sialkot, PAK.
Mahima KhatriMedicine and Surgery, Dow University of Health Sciences, Karachi, PAK.
Satesh KumarMedicine and Surgery, Shaheed Mohtarma Benazir Bhutto Medical College, Karachi, PAK.
Fnu SapnaInternal Medicine, Detroit Medical Center, Detroit, USA.
Arjan DassInternal Medicine, Willis-Knighton Health System, Shreveport, USA.
Giustino VarrassiPain Medicine, Paolo Procacci Foundation, Rome, ITA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to assess the effectiveness and safety of azilsartan-medoxomil/chlorthalidone (AZI-M/CT) compared to olmesartan-medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients with hypertension. Systematic searches were conducted on PubMed, Google Scholar, and ClinicalTrials.gov, starting from their establishment until March 15, 2023. The purpose of these searches was to locate original reports that compare the effectiveness of AZI-M/CT and OLM/HCTZ in treating hypertension. Data on various characteristics at the beginning and end of the studies were gathered. The analyses were carried out using Review Manager 5.4.1 (The Nordic Cochrane Center, The Cochrane Collaboration, 2014, Odense, Denmark) and STATA 16.0 software (Stata Corp. LP, College Station, TX, USA). Risk ratios (RRs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs) were calculated as part of the study. A total of 3,146 individuals from four separate investigations were included in the study, with 1,931 individuals receiving AZI-M/CT and 1,215 individuals receiving OLM/HCTZ. The combined analysis revealed that the average diastolic blood pressure (DBP) was significantly lower in the AZI-M/CT group compared to the OLM/HCTZ group (WMD -2.64 [-2.78, -2.51];

Indexed as

azilsartan-medoxomilazi-m/ctchlorthalidonemeta-analysisolmesartanolm/hctzsystematic review

Identifiers

PMID37525792
PMCPMC10387287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.